Invitae, a genetics company, agreed to acquire ArcherDX, a genomics analysis company democratizing precision oncology, for $1.4bn. "From the beginning, Invitae's goal has been to aggregate the world's genetic tests into a single platform in service of our mission to bring comprehensive genetic information into mainstream medicine. Today, we take another major step forward in that effort," Sean George, Invitae CEO.